Monoamine oxidase inhibitor-induced blockade of locomotor sensitization to quinpirole: Role of striatal dopamine uptake inhibition

Neuropharmacology

Volumn 43, Issue 3, 2002, Pages 385-393

  Culver, K E ^a   Rosenfeld, J M ^a   Szechtman, H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Clorgyline; Dopamine; Locomotion; Mouthing; Pargyline; Sensitization

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CLORGYLINE; DOPAMINE; MONOAMINE OXIDASE INHIBITOR; PARGYLINE; QUINPIROLE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DOPAMINE METABOLISM; DOPAMINE UPTAKE; DRUG EFFECT; DRUG SENSITIZATION; LOCOMOTION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BRAIN CHEMISTRY; CLORGYLINE; DOPAMINE; DOPAMINE AGONISTS; MALE; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; NEOSTRIATUM; PARGYLINE; PREFRONTAL CORTEX; QUINPIROLE; RATS; RATS, LONG-EVANS; STEREOTYPED BEHAVIOR;

EID: 0036710686     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(02)00128-4     Document Type: Article

References (38)

1. Banks K.E., Gratton A. Possible involvement of medial prefrontal cortex in amphetamine-induced sensitization of mesolimbic dopamine function. European Journal of Pharmacology. 282:1995;157-167.
2. Campbell I.C., Robinson D.S., Lovenberg W., Murphy D.L. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. Journal of Neurochemistry. 32:1979;49-55.
3. Campbell I.C., Durcan M.J., Cohen R.M., Pickar D., Chugani D., Murphy D.L. Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. Pharmacology Biochemistry and Behavior. 23:1985;921-925.
4. Canadian Council on Animal Care . Guide to the Care and Use of Experimental Animals. 2:1984;CCAC, Ottawa, Ont, Canada.
5. Canadian Council on Animal Care . Guide to the Care and Use of Experimental Animals. 1:1984;CCAC, Ottawa, Ont, Canada. third ed.
6. Clement H.W., Grote C., Wesemann W. In vivo studies on the effect of monoamine oxidase inhibitors on dopamine and serotonin metabolism in rat brain areas. Journal of Neural Transmission Suppl. 32:1990;85-88.
7. Colzi A., d'Agostini F., Kettler R., Borroni E., Da Prada M. Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. Journal of Neural Transmission Suppl. 32:1990;79-84.
8. Culver K.E., Szechtman H. Monoamine oxidase sensitive site implicated in sensitization to quinpirole. European Journal of Pharmacology. 339:1997;109-111.
9. Culver K.E., Szechtman H. The effect of intermittent and continuous clorgyline (CLG) administration on locomotor sensitization induced by the dopamine agonist quinpirole (QNP). Society for Neuroscience Abstracts. 25:1999.
10. Culver K.E., Rosenfeld J.M., Szechtman H. A switch mechanism between locomotion and mouthing in sensitization to quinpirole in rats. Psychopharmacology. 151:2000;202-210.
11. Culver K.E., Szechtman H. Chronic R041-1049 treatment blocks quinpirole-induced locomotor sensitization. Society for Neuroscience Abstracts. 26:2000.
12. Culver K.E., Szechtman H. Quinpirole-induced sensitization: Implications for a novel MAOI-displaceable quinpirole binding site. Society for Neuroscience Abstracts. 27:2001.
13. Deutch A.Y. The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. Journal of Neural Transmission. 36:1992;61-89.
14. Deutch A.Y., Clark W.A., Roth R.H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Research. 521:1990;311-315.
15. 1 receptor modulation of the meso-accumbens dopamine response to stress: an electrochemical study in freely moving rats. Brain Research. 715:1996;86-97.
16. Eilam D., Szechtman H. Biphasic effect of D-2 agonist quinpirole on locomotion and movements. European Journal of Pharmacology. 161:1989;151-157.
17. Fang J., Yu P.H. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropsychopharmacology. 33:1994;763-768.
18. Hoffman D.C., Wise R.A. Locomotor-activating effects on the D2 agonist bromocriptine show environment-specific sensitization following repeated injections. Psychopharmacology. 107:1992;277-284.
19. Jaskiw G.E., Weinberger D.R., Crawley J.N. Microinjection of apomorphine into the prefrontal cortex of the rat reduces dopamine metabolite concentrations in microdialysate from the caudate nucleus. Biological Psychiatry. 29:1991;703-706.
20. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Behavioral Pharmacology. 4:1991;315-334.
21. Lai J.C.K., Leung T.K.C., Guest J.F., Lim L., Davison A.N. The monoamine oxidase inhibitors clorgyline and L-deprenyl also affect the uptake of dopamine, noradrenaline and serotonin by rat brain synaptosomal preparations. Biochemical Pharmacology. 29:1980;2763-2767.
22. 3H]quinpirole binding in rat striatal membranes. European Journal of Pharmacology. 246:1993;171-178.
23. 3H]quinpirole binding in brain by monoamine oxidase inhibitors: Evidence for a potential novel binding site. Journal of Pharmacology and Experimental Therapeutics. 278:1996;145-153.
24. A-deficient mice. Life Science. 70:2001;229-241.
25. Lindvall O., Bjorklund A. Neuroanatomical localization of dopamine in the brain and spinal cord. Henn F.A., DeLisi L.E., Handbook of Schizophrenia. Neurochemistry and Neuropharmacology of Schizophrenia. 2:1987;49-99 Elsevier Science, Amsterdam.
26. Mattingly B.A., Gotsick J.E. Conditioning and experimental factors affecting the development of sensitization to apomorphine. Behavioral Neuroscience. 103:1989;1311-1317.
27. Mitchell J.B., Gratton A. Partial dopamine depletion of the prefrontal cortex leads to enhanced mesolimbic dopamine release elicited by repeated exposure to naturally reinforcing stimuli. Journal of Neuroscience. 12:1992;3609-3618.
28. Pycock C.J., Kerwin R.W. Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on neurotransmitter systems in subcortical sites in the rat. Journal of Neurochemistry. 34:1980;91-99.
29. Robinson T.E., Becker J.B. Enduring change in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research. 396:1986;157-198.
30. Segal D.S., Schuckit M.A. Animal models of stimulant-induced psychosis. Creese, . Stimulants:Neurochemical, Behavioral and Clinical Perspectives. 1983;131-167 Raven Press, New York.
31. Sullivan R.M., Szechtman H. Asymmetrical influence of mesocortical dopamine depletion on stress ulcer development and subcortical dopamine synthesis in rats: implications for psychopathology. Neuroscience. 65:1995;757-766.
32. Sullivan R.M., Talangbayan H., Einat H., Szechtman H. Effects of quinpirole on central dopamine systems in sensitized and non-sensitized rats. Neuroscience. 83:1998;781-789.
33. Szechtman H., Dai H., Mustafa S., Einat H., Sullivan R.M. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacology Biochemistry and Behavior. 48:1994;921-928.
34. Szechtman H., Talangbayan H., Canaran G., Dai H., Eilam D. Dynamics of behavioral sensitization induced by the dopamine agonist quinpirole and a proposed central energy mechanism. Psychopharmacology. 115:1994;95-104.
35. Szechtman H., Culver K.E., Eilam D. Role of dopamine systems in obsessive-compulsive disorder: Implications from a novel psychostimulant-induced animal model. Polish Journal of Pharmacology. 51:1999;55-61.
36. Szumlinski K.K., Allan M., Talangbayan H., Tracey A., Szechtman H. Locomotor sensitization to quinpirole: environment-modulated increase in efficacy and context-dependent increase in potency. Psychopharmacology. 134:1997;193-200.
37. Wayment H.K., Schenk J.O., Sorg B.A. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: Role of monoamine uptake and monoamine oxidase inhibition. Journal of Neuroscience. 21:2001;35-44.
38. 2) and evidence for the expression of the transporter in the brain. Journal of Biological Chemistry. 273:1998;32776-32786.